Articles related to Family Medicine/General Practice
Gabapentin-Involved Overdose Deaths Increased Between 2019 and 2020
As use of gabapentin in the United States has been steadily increasing in recent years, researchers from the CDC have found that, among the 62,652 overdose deaths that occurred between 2019 and 2020, 58,362 of these cases had documented toxicology results.
Clinical Pharmacology May 24th 2022
FDA Approves First-in-Class Treatment for Type 2 Diabetes
Mounjaro (tirzepatide) is a first-in-class, once-weekly, dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist that integrates the actions of both incretins into a single molecule. It enhances first- and second-phase insulin secretion, and reduces glucagon levels, both in a glucose-dependent manner. The FDA approval of Mounjaro as an adjunct therapy to diet and exercise for adults with type 2 diabetes was based on clinical trials where treatment with Mounjaro resulted in statistically significant reduction in both A1c and weight vs. semaglutide, insulin degludec, and insulin glargine.
Endocrinology, Diabetes, Metabolism May 24th 2022
IDSA Offers Guidance on Managing Drug Interactions with Nirmatrelvir/Ritonavir
The Infectious Diseases Society of America (IDSA) has issued guidance on managing drug interactions with nirmatrelvir/ritonavir (Paxlovid). Specifically, the IDSA recommends clinicians take six steps to minimize the risk of drug interactions for patients with COVID-19 who are eligible for nirmatrelvir/ritonavir.
Allergy & Immunology May 24th 2022
Diabetes Screening by Race and Ethnicity in the United States: Equivalent Body Mass Index and Age Thresholds
Among adults aged 35 years or older with a body mass index (BMI) of 25 kg/m2, the prevalence of diabetes in Asian, Black, and Hispanic Americans was significantly higher than that in White Americans. Using screening thresholds specific to race and ethnicity has the potential to reduce disparities in diabetes diagnosis.
Endocrinology, Diabetes, Metabolism May 17th 2022
Managing stage 1 hypertension: Consider the risks, stop the progression
There haven’t been any national guidelines developed for managing patients with stage 1 hypertension who don’t respond to lifestyle modification. This population represents an important guideline gap: most patients with stage 1 hypertension progress to stage 2 hypertension, which increases the risk for cardiovascular events. The AHA has published a scientific statement to fill the gap – if lifestyle modification fails to reduce blood pressure, consider pharmacotherapy.
Cardiology May 17th 2022